Skip to main content
Premium Trial:

Request an Annual Quote

Japan s Mitsui Makes Equity Investment in Correlogic

NEW YORK, Feb. 10 (GenomeWeb News) -  Tokyo-based Mitsui today announced an equity investment in Correlogic Systems of Bethesda, Md.

 

Terms of the deal were not disclosed.

 

Mitsui, Japan's second largest trading house, behind Mitsubishi, said that it has also signed a memorandum of understanding to explore creating a Japan-based joint venture for the deployment of Correlogic's proteomics-based diagnostic testing technology.

 

The investment was conducted by the business development segment of the Mitsui's Performance Chemicals unit. The company said it was attracted by the potential of Correlogic's technology to detect a range of disease states. Mitsui will be exploring the validation of the technology with Japanese patients for a number of disease states, including cancers most prevalent in Japan, the company said in a statement.

Correlogic has entered into licensing agreements with Laboratory Corp. of America and Quest Diagnostics for the North American market development and commercialization of a diagnostic test applying Correlogic's technology to ovarian cancer.

 

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.